SecBot SecBot
Insider Cluster ·Filed Mar 31, 2026

ZBIO

Zenas BioPharma, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago
Insider cluster: 2 insiders, $2.2M total
Actionable Insight ◆ Mixed

Monitor for potential insider advantage concerns given purchases just before a large dilutive capital raise. Assess whether insider buying reflects confidence in long-term prospects or was timed before negative price impact from financing. Watch for further insider activity and commentary on use of proceeds.

DirectionMixed
Confidencelow
Horizonweeks
Final — all horizons settled through T+60d
ZBIO ▲ +25.49% at T+60d
NEUTRAL call +25.49% · α vs SPY +12.40% · entry $20.36 → $25.55
Entry = T+0 close
Mar 31, 2026
via day close
T+1d
+5.40%
call +5.40% · α +5.31%
$21.46
settled 7mo ago
T+5d
+4.52%
call +4.52% · α +0.75%
$21.28
settled 7mo ago
T+20d
-5.11%
call -5.11% · α -14.79%
$19.32
settled 6mo ago
T+60d
+25.49%
call +25.49% · α +12.40%
$25.55
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Analysis based on filing metadata only — document content was unavailable. However, a recent insider trading cluster shows CEO and director buying $2.5M in shares, coinciding with a $200M convertible note offering and a $100M equity raise. Insiders may have had advance knowledge of the dilutive capital raise.

Key Financial Metrics

Direction
buying

Key Facts

  • Insider cluster involving CEO and director with $2.5M in open-market purchases over 2 days
  • Concurrent with $200M convertible notes and $100M equity offering announced within the same period
  • Insiders may have had material non-public information about upcoming dilution
  • CEO Leon Moulder Jr. participated in both purchase transactions

Financial Impact

Approximately $2.5M in insider buying, offset by $300M in new capital raises (convertible notes and equity) announced within 1 day, leading to potential shareholder dilution

dilutioninsider sentimentcashequity

Risk Factors

  • Perception of insider advantage if executives bought shares before announcing dilution
  • Downward pressure on stock price from $300M in new securities issuance
  • Convertible notes could lead to significant future dilution if stock price rises

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

Report based on filing metadata.

18 reports for ZBIO
Performance horizon
75% Hit rate @ T+60 3 of 4 directional calls Went positive at some point 4 of 4 best @ T+60▲ +73.98%May 28, 2026
Filters
Rows
Reports for ZBIO — sortable, filterable
TypeNow
Oct 16, 2026
11d ago
Press Release
NEUTRAL ★ 2/10
$26.71awaiting T+60—$27.30 (+2.21%)
Oct 13, 2026
14d ago
8-K
NEUTRAL ★ 4/10
$25.16awaiting T+60—$27.30 (+8.51%)
Sep 22, 2026
5w ago
Press Release
NEUTRAL ★ 4/10
$33.05awaiting T+60—$27.30 (−17.40%)
Sep 18, 2026
5w ago
Press Release
NEUTRAL ★ 2/10
$32.55awaiting T+60—$27.30 (−16.13%)
Sep 11, 2026
6w ago
S-3ASR
NEUTRAL ★ 5/10
$31.91awaiting T+60—$27.30 (−14.45%)
May 28, 2026
21w ago
Press Release
BULLISH ★ 7/10
$18.56 $32.29▲ +73.98%▲ +72.24%$27.30 (+47.09%)
May 19, 2026
23w ago
Press Release
BULLISH ★ 7/10
$17.84 $29.20▲ +63.68%▲ +57.39%$27.30 (+53.03%)
May 13, 2026
23w ago
Press Release
NEUTRAL ★ 4/10
$19.93 $32.43▲ +62.72%▲ +58.28%$27.30 (+36.98%)
May 13, 2026
23w ago
8-K
NEUTRAL ★ 4/10
$19.93 $32.43▲ +62.72%▲ +58.28%$27.30 (+36.98%)
May 13, 2026
23w ago
Press Release
NEUTRAL ★ 5/10
$19.93 $32.43▲ +62.72%▲ +58.28%$27.30 (+36.98%)
Showing 10 of 18

US Market Status

Market Closed — Opens Wed (16h 52m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 31, 2026